In a research report to clients Monday, Grigo initiated coverage on Spectra7 Microsystems with a “Strong Buy” recommendation and 12-month target price of $1.00, implying a return of 69.5% at the time of publication.
Markham-based Spectra7 builds integrated circuits that make electronic products smaller, lighter and faster. Grigo says the company’s technology is applicable in multiple verticals such as tablets, smartphones and, most immediately, the virtual reality space. Spectra 7 currently has 39 patents, with 13 more pending.
While Spectra7’s opportunity is both broad and specific, Grigo says it can solve a one vexing problem immediately.
“SEV’s analog chip has addressed a long-standing problem that has plagued old versions of VR head mounted displays (―HMDs‖), namely weight, latency, price, and size. Prior to SEV’s solution, VR head gear was a mishmash of four cables (data, video, audio and power), which was cumbersome to wear and suffered from latency effect (slow speeds led to motion sickness). SEV’s analog chip has enabled HMD manufacturers to reduce four cables to one, which led to a weight reduction of over 90% and in the process has made VR headgear more consumer friendly,” said Grigo.
Grigo says Spectra7 also has a “massive” opportunity in the HD TV market, which is shifting from 1080p resolution to 4K resolution. He thinks the company’s recent win with a tier one TV manufacturer is the first of many such victories it will enjoy.
Beacon Securities analyst Russell Stanley maintained his “Buy” rating and C$3.00 target on Intermap Technologies (Intermap Technologies Stock Quote, Chart,… [Read More]
Desjardins analyst Benoit Poirier reiterated his “Buy” rating on BRP (BRP Stock Quote, Chart, News, Analysts, Financials TSX:DOO) and raised… [Read More]
In a March 27 report, Haywood analyst Neal Gilmer reiterated his “Buy” rating and $0.25 target price on Auxly Cannabis… [Read More]
In an interview on BNN Bloomberg’s Market Call on March 25, Caldwell Investment Management president and CEO Brendan Caldwell said… [Read More]
In a March 26 note, Paradigm Capital analyst Daniel Rosenberg maintained his “Buy” rating and $2.50 target on Pivotree (Pivotree… [Read More]
In a March 26 report, Stifel analyst Justin Keywood reiterated his “Buy” rating and C$8.00 target on WELL Health Technologies… [Read More]